Update of human papillomavirus vaccination
Open Access
- 1 January 2015
- journal article
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 58 (4) , 313-318
Abstract
Kim BG. J Korean Med Assoc. 2015 Apr;58(4):313-318. http://dx.doi.org/10.5124/jkma.2015.58.4.313Keywords
This publication has 16 references indexed in Scilit:
- Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccinationHuman Vaccines & Immunotherapeutics, 2014
- Cross-roads in the classification of papillomavirusesVirology, 2013
- Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young WomenJAMA, 2013
- Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2012
- HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protectionVaccine, 2011
- Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialBMJ, 2010
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 yearsHuman Vaccines, 2009
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital DiseasesNew England Journal of Medicine, 2007
- Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysisThe Lancet, 2005